Bioethic Pharma Launches JANVAX: Innovative Treatment for Chronic Inflammatory Conditions
Admin05/07/2024 07:00
Bioethic Pharma, the exclusive representative of Varifarma Laboratory in Paraguay, is pleased to announce the launch of JANVAX, a revolutionary medication based on tofacitinib citrate. Developed by the prestigious Varifarma Laboratory, JANVAX is designed for the treatment of various chronic inflammatory conditions, offering new hope to both adult and pediatric patients.
The official launch event for JANVAX took place on July 4, 2024, at Jazz Cube in Asunción. The event featured prominent national and international physicians specializing in Rheumatology and Gastroenterology, who shared their experiences and insights on the impact of JANVAX in clinical practice.
Left: Dr. Aldo Ojeda - President of the Paraguayan Society of Rheumatology
Dr. Guillermo Veitia - Gastroenterology Specialist and President of PANCCO
Dr. Enrique Soriano - Rheumatology Specialist at Hospital Italiano de Buenos Aires
Dionisio Sosa, Specialty Line Manager
Edgar Villalba, Director of Bioethic Pharma
Danilo Villano, Commercial Manager of Bioethic Pharma
“Renowned national and international physicians specializing in Rheumatology and Gastroenterology”
“Distinguished national and international physicians specializing in Rheumatology and Gastroenterology”